IA · State regulatory reference
Iowa.
Moderate
Iowa applies standard telemedicine and compounding frameworks with no peptide/GLP-1-specific rule and no documented board enforcement located. Telemedicine practice is governed by IAC 481-655.9 (recodified from 653-13.11, effective May 2025): a valid physician-patient relationship may be established through a synchronous telemedicine encounter, and a static internet questionnaire is expressly not an acceptable exam. Compounding under IAC 657 ch. 20 adopts USP <795> (nonsterile, 657-20.3) and USP <797> (sterile, 657-20.4); the 'essentially a copy of an approved drug' limit (657-20.12) tracks federal 503A.
Last reviewed · 2026-05-25 · verified entry
Agencies
TPC notes
Telehealth
Under IAC 481-655.9, the physician-patient relationship and prescribing can occur via a synchronous audio-video telemedicine encounter (no prior in-person exam required) where the standard of care allows and the technology supports an informed diagnosis; audio-only, email, or a static questionnaire alone does not qualify.
Compounding
IAC 657-20.3/20.4 require Iowa-licensed pharmacies to follow current USP <795> (nonsterile) and <797> (sterile); 657-20.12 restricts compounding copies of approved drugs to a documented clinically significant difference or an active FDA shortage, mirroring federal 503A with no GLP-1-specific carve-out.
Sources